Maximum duration of treatment: 16 weeks, ESK-001 clinical trials

A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study in Patients with Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 (ONWARD2)

This study is testing a new medicine, ESK-001, for people with moderate to severe plaque psoriasis. Researchers want to see if it's safe and helps clear up skin patches better than a dummy pill or an existing medicine (Otezla).